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Abstract
Background: The aim of this study was to evaluate the association between health-related quality
of life (HRQL) and disease severity using lung function measures.
Methods: A survey was performed in subjects with COPD in Sweden. 168 subjects (70 women,
mean age 64.3 years) completed the generic HRQL questionnaire, the Short Form 36 (SF-36), the
disease-specific HRQL questionnaire; the St George's Respiratory Questionnaire (SGRQ), and the
utility measure, the EQ-5D. The subjects were divided into four severity groups according to FEV1
per cent of predicted normal using two clinical guidelines: GOLD and BTS. Age, gender, smoking
status and socio-economic group were regarded as confounders.
Results: The COPD severity grades affected the SGRQ Total scores, varying from 25 to 53
(GOLD p = 0.0005) and from 25 to 45 (BTS p = 0.0023). The scores for SF-36 Physical were
significantly associated with COPD severity (GOLD p = 0.0059, BTS p = 0.032). No significant
association were noticed for the SF-36, Mental Component Summary scores and COPD severity.
Scores for EQ-5D VAS varied from 73 to 37 (GOLD I-IV p = 0.0001) and from 73 to 50 (BTS 0-III
p = 0.0007). The SGRQ Total score was significant between age groups (p = 0.0047). No significant
differences in HRQL with regard to gender, smoking status or socio-economic group were noticed.
Conclusion: The results show that HRQL in COPD deteriorates with disease severity and with
age. These data show a relationship between HRQL and disease severity obtained by lung function.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality worldwide and is
currently the fourth leading cause of death in the US [1].
It is a slowly progressive disease, characterized by lung
function impairment with airway obstruction [2,3]. Com-
mon symptoms are cough, sputum production and short-
ness of breath. Smoking and different air pollutants, such
as are well-known risk factors for COPD [3,2].
The prevalence of COPD varies considerably between
countries and areas, from 3% in India [4] to 23% in the
inner-city population of Manchester, UK [5]. The US
National Health and Nutrition Examination Survey
(NHANES) III survey puts the prevalence of COPD in the
US at 7% [6]. The figure in Spain is similar, 9% [7]. In
Sweden, the prevalence of COPD in those aged above 45
years was estimated to be 8% according to the British Tho-
racic Society (BTS) criteria and 14% according to the Glo-
bal Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [8]. However, there are a considerable
number of subjects with COPD who have not been diag-
nosed as such. In Europe and also in Sweden only one-
quarter to one-third of those with COPD have been diag-
nosed as having COPD or with different labelling of the
disease [8-11].
Over the past decade, more and more research on the
development and validation of questionnaires has been
undertaken to quantify the impact of disease on daily life
and well-being from the COPD subject's point of view
[12]. Health-related quality of life (HRQL), and prefer-
ence-based HRQL instruments (utility instruments) are
increasingly used in clinical studies. Although their use is
established in many fields, such as oncology and gastroin-
testinal disease, questionnaires are rarely used as primary
endpoints in randomised clinical studies of respiratory
disease. One possible reason may be the lack of informa-
tion about the patients' deterioration in HRQL when the
disease progresses. The Medical Outcomes Study Short
Form 36 (SF-36) and St George's Respiratory Question-
naire (SGRQ) are generic and disease-specific HRQL ques-
tionnaires, respectively [13,14]. The SF-36 has been used
in a number of therapeutic areas, including COPD, while
the SGRQ has been widely used in both COPD and
asthma research. The EQ-5D is a generic, preference-based
utility measure and has been used in a number of thera-
peutic areas [15].
The aim of the present study was to evaluate the associa-
tion between HRQL and COPD stages using forced expir-
atory volume in one second as a percentage of predicted
normal values (FEV1 % predicted) by means of two clini-
cal guidelines for COPD, taking into account the influ-
ence on HRQL of age, gender, smoking status and socio-
economic background. The association between HRQL
and forced vital capacity as a percentage of predicted nor-
mal values (FVC % predicted) was also evaluated.
Methods
Study sample
A total of 202 subjects with COPD, recruited from a rep-
resentative sample of the general population in northern
Sweden, were invited; 176 subjects took part in this survey
and data from 168 subjects were available [16]. The study
cohort was derived from the Obstructive Lung Disease in
Northern Sweden (OLIN) Studies [8,9], which has previ-
ously been described in detail [16].
Procedure
After initial instruction from the administrator, a qualified
nurse, the questionnaires were completed unaided by
subjects in the order SF-36, SGRQ and EQ-5D. A few sub-
jects did not complete all questionnaires.
Definition and severity of COPD
The subjects were divided into four severity groups
according to FEV1% predicted (pre-bronchodilator) using
two different guidelines: the updated version (not yet
published) of the GOLD guidelines [3] and the BTS guide-
lines [2]. The definition and severity criteria are described
in Table 1. Calculation of FEV1predicted normal values for
FEV1 was based on the reference values from ERS guide-
lines. In addition, levels of FVC % predicted were also
used in the analysis instead of COPD severity stages.
HRQL questionnaires
Short Form 36
The most widely used generic questionnaire, the Medical
Outcomes Study Short Form 36 (SF-36), has been widely
accepted in recent years as the best generic HRQL meas-
urement. It contains 36 items divided into eight domains:
Physical Functioning (PF), Role-Physical (RP), Bodily
Pain (BP), General Health (GH), Vitality (VT), Social
Functioning (SF), Role-Emotional (RE) and Mental
Health (MH). These domains create a profile of the sub-
ject. Two summary scores can also be aggregated, the
Physical Component Summary (PCS) and the Mental
Component Summary (MCS). Scores range from 0 to 100,
with higher scores representing better HRQL.
St George's Respiratory Questionnaire
The best-known and most frequently used disease-specific
HRQL questionnaire for respiratory diseases, is the St
George's Respiratory Questionnaire (SGRQ) [14,17]. The
SGRQ is a standardized, self-administered questionnaire
for measuring impaired health and perceived HRQL in
airways disease. It contains 50 items, divided into three
domains: Symptoms, Activity and Impacts. A score is cal-
culated for each domain and a total score, including allHealth and Quality of Life Outcomes 2005, 3:56 http://www.hqlo.com/content/3/1/56
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items, is also calculated. Each item has an empirically
derived weight. Low scores indicate a better HRQL. Recent
publications by the developer (PW Jones) have confirmed
that the minimal important difference relevant to the
patients (MID) is 4 on a scale of 0 to 100 [18,19].
EQ-5D
The EQ-5D is a generic, preference-based utility question-
naire and consists of two parts, the EQ-5D VAS and the
EQ-5D index. The EQ-5D has been used in a number of
therapeutic areas and contains a vertical rating scale from
0 to 100 (EQ-5D VAS), with 0 = death/worst possible
health and 100 = best possible health. The EQ-5D index is
a five-item questionnaire ranging from 0 to 1. The items
consist of mobility, self-care, usual activity, pain/discom-
fort and anxiety/depression. Each item has three levels: no
problem, some problem and severe problem [15]. For the
EQ-5D index, 0.03 has been regarded as the MID [20].
Statistical analysis
Statistical analysis was performed using an analysis of cov-
ariance model with HRQL scores as dependent variable.
Three different approaches to analysis were performed
using different classification of severity of COPD from
GOLD and BTS guidelines. This classification was used as
factor in the analysis. In all cases age, gender, smoking sta-
tus and socio-economic background was used as covari-
ates. These variables showed sign of influence on the
HRQL measures and for the sake of comparability a uni-
fied model was selected for the analysis. An additional
classification of severity based on FVC % predicted nor-
mal was also investigated with the same model with clas-
sification into four groups: stage I: > 95%, stage II: 95-
81%, stage 3: 80-66% and stage IV; < 66%. These levels
were chosen to have approximately equal number of
patients in each group. Data presented in tables are
adjusted least-square means from the adopted model.
Results
Subject characteristics
The mean age of the 168 subjects (70 women) was 64.3
years (range: 28–80 years). In the six age groups (the low-
est < 45 and the highest > 79 years), 57 of the subjects
were smokers and 85 were ex-smokers. Three socio-eco-
nomic groups were identified (manual employees, non-
manual employees and unemployed including house-
wives). Of the 138 'employees', 65 were still working and
73 had retired, and of these, 40 had retired before the nor-
mal age of retirement. Table 2 shows the subjects'
characteristics.
Table 1: Severity criteria of COPD
Global Initiative for Chronic Obstructive Lung Disease, GOLD [3]: FEV1/FVC < 70%
I: Mild COPD FEV1 ≥ 80% predicted
II: Moderate COPD FEV1 50- < 80% predicted
III: Severe COPD FEV1 30- < 50% predicted
IV: Very severe COPD FEV1 < 30% predicted
British Thoracic Society, BTS [2]: FEV1/VC < 70% and FEV1 < 80% predicted
I: Mild COPD FEV1 60- < 80% predicted
II: Moderate COPD FEV1 40-59% predicted
III: Severe COPD FEV1 < 40% predicted
A group labelled BTS stage 0 was created for subjects with FEV1 ≥ 80% predicted: i.e. identical with mild COPD according to the GOLD criteria.
Table 2: Subject characteristics
Characteristic Mean data (range)
n, total number agreed 176
Men/women n = 168 98/70
Mean age, years (range) n = 168 64.3 (28–80)
FEV1, L (range) n = 159 1.76 (0.46–4.12)
FEV1 % predicted (range) n = 159 62 (18–118)
Smoking status n = 171 Smoker, n = 57 Non-smoker, n = 29 Ex-smoker, n = 85
Socioeconomic group n = 174 Manual employees, n = 78 Non-manual employees, n = 60 Unemployed 
incl. housewives, n = 36Health and Quality of Life Outcomes 2005, 3:56 http://www.hqlo.com/content/3/1/56
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HRQL in relation to COPD severity according to GOLD
The differences in SF-36 PCS between the four severity
groups were statistically significant (p = 0.0059). The
scores for SF-36 (PCS) were 42 in the stage I group and 29
in the stage IV group. The corresponding scores for SF-36
MCS were 55 and 48 in stages I and IV respectively (p =
0.19) (Table 3).
There was also a statistically significant difference in the
SGRQ scores between the severity groups (p = 0.0005).
The severity grades affected the level of SGRQ Total as fol-
lows: stage I: 25, stage II: 32, stage III: 36 and stage IV: 53
(Table 3, Figure 1).
The scores for EQ-5D VAS were 73 in stage I and 37 in
stage IV (p = 0.0001). EQ-5D index showed the following
Table 3: Health-related quality of life scores, adjusted mean values (± SD) – GOLD criteria
Scale FEV1 % predicted
≥ 80% Stage I n = 26 79-50% Stage II n = 91 49-30% Stage III n = 33  < 30% Stage IV n = 9 p-value (all stages)
SF-36 PCS 42(12) 42(12) 40(10) 29(12) 0.0059
SF-36 MCS 55(8) 51(11) 52(12) 48(18) 0.19
SGRQ Total 25(20) 32(20) 36(20) 53(23) 0.0005
EQ-5D VAS 73(21) 65(24) 62(21) 37(28) 0.0001
EQ-5D index 0.84(0.15) 0.73(0.23) 0.74(0.25) 0.52(0.26) 0.0008
SGRQ, Total score (adjusted mean values) in GOLD and BTS stages Figure 1
SGRQ, Total score (adjusted mean values) in GOLD and BTS stages. p-values by test for trend.
SGRQ, Total score (mean values)
25
32
36
53
25
32 34
45
0
10
20
30
40
50
60
70
>80%/>80% 79-50%/80-60% 49-30%/59-40% <30%/<40%
FEV1 %p r e d
GOLD, p=0.0005 BTS, p=0.0009
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scores: stage I: 0.84 and stage IV: 0.52 (p = 0.0008) (Table
3).
HRQL in relation to COPD severity according to BTS
The scores for SF-36 (PCS) were 42 in the group labelled
stage 0 and 35 in stage III (p = 0.032). The corresponding
scores for SF-36 MCS were 55 and 50 in stages 0 and III,
respectively (p = 0.29) (Table 4).
The severity grades affected the level of SGRQ Total scores
as follows: stage 0: 25, stage I: 32, stage II: 34, and stage
III: 45. There was a statistically significant difference in the
SGRQ Total scores between the severity groups (p =
0.0023) (Table 4, Figure 1).
The scores for EQ-5D VAS were 73 in stage 0 and 50 in
stage III (p = 0.0007). The EQ-5D index scores were 0.84
and 0.63 in stages 0 and III, respectively (p = 0.0041)
(Table 4).
Influence of age, gender, smoking status and socio-
economic group
The level of SF-36 PCS varied in the age groups from 44 (
< 45 years) to 36 ( > 79 years), with no statistical signifi-
cance between the age groups. The level of SF-36 MCS was
somewhat higher, 56 in the low age group and 51 in the
high age group (not significant). The scores for SGRQ var-
ied from 29 ( < 45 years) to 44 ( > 79 years) and they were
statistically significant (p = 0.0047) (Figure 2). The scores
for EQ-5D VAS varied as follows: 86 ( < 45 years) to 81 (
> 79 years). No statistical difference in EQ-5D VAS and
EQ-5D index between the age groups could be seen.
The gender comparison showed only a statistically signif-
icant difference in SF-36 PCS, with scores of 44 for the
men and 35 for the women (p = 0.0005).
The mean scores for SGRQ Total were 26, 36 and 31 in the
non-smoker, ex-smoker and smoker groups, respectively
(not significant).
No significant differences were seen in the other two
instruments. Socio-economic group showed no difference
for any instrument.
HRQL in relation to FVC % predicted
The four stages of FVC % predicted ( > 95%, 95-81%, 80-
66%, < 66%) had an impact on HRQL similar to the stages
of FEV1 % predicted outlined from GOLD and BTS. SGRQ
total score varied from 26 ( > 95%) to 43 ( < 66%) (p =
0.0002) (Table 5). Using the GOLD stages, the number of
patients was unequally distributed and the SGRQ Total
scores were 26 ( > 80%, n = 81), 40 (79-50%, n = 68) and
46 (49-30%, n = 10) (p < 0.0001). No patient had a value
less than 30% predicted.
Correlations between the instruments
Table 6 shows the Pearson correlation coefficients
between the different instruments and FEV1 % and FVC %
predicted. All the questionnaires were correlated with
each other. The correlation coefficients between SGRQ
and SF-36 PCS/MCS were -0.62 and -0.42, respectively.
The lowest correlation was seen between SF-36 MCS and
SF-36 PCS (r = 0.22). The correlations between SGRQ and
either FEV1 % predicted or FVC % predicted were similar
(-0.34 and -0.37, respectively).
Discussion
The present study confirms that disease severity (based on
FEV1) and age influenced HRQL among subjects with
COPD. HRQL was strongly related to impaired FEV1 in
our study, which is in contrast to some previous studies
[21]. The relationship between disease severity using
FEV1% predicted and HRQL was made obvious by staging
the disease according to the GOLD and BTS guidelines.
Once COPD has been diagnosed, neither gender, smoking
status nor socio-economic group predicted the level of
HRQL.
The relationship between disease severity and HRQL
across different chronic conditions, such as ischemic
Table 4: Health-related quality of life scores, adjusted mean values (± SD) – BTS criteria
Scale FEV1 % predicted
≥ 80% Stage 0 n = 26 79-60% Stage I n = 63 59-40% Stage II n = 47  < 40%Stage III n = 23 p-value (all stages)
SF-36 PCS 42(12) 43(11) 40(13) 35(11) 0.032
SF-36 MCS 55(8) 50(10) 54(11) 50(15) 0.29
SGRQ Total 25(20) 32(20) 34(19) 45(22) 0.0023
EQ-5D VAS 73(21) 68(20) 60(28) 50(25) 0.0007
EQ-5D index 0.84(0.15) 0.74(0.21) 0.72(0.28) 0.63(0.25) 0.0041Health and Quality of Life Outcomes 2005, 3:56 http://www.hqlo.com/content/3/1/56
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SGRQ, Total score (mean values) in the six age groups Figure 2
SGRQ, Total score (mean values) in the six age groups. p-values by test for trend.
Table 5: Health-related quality of life scores, adjusted mean values (± SD) using FVC% predicted normal value
Scale FVC % predicted
 > 95% n = 35 95-81% n = 33 80-66% n = 40  < 66% n = 34 p-value (all stages)
SF-36 PCS 44(11) 45(11) 38(12) 35(10) 0.0008
SF-36 MCS 53(9) 52(10) 53(11) 49(14) 0.28
SGRQ Total 26(17) 29(17) 37(22) 43(20) 0.0002
EQ-5D VAS 71(19) 69(24) 63(25) 49(25) 0.0002
EQ-5D index 0.79(0.18) 0.80(0.19) 0.71(0.27) 0.62(0.26) 0.0017
Table 6: Pearson's correlation coefficients (r)
SF-36 PCS SF-36 MCS SGRQ Total EQ-5D VAS EQ-5D index FEV1 % predicted FVC % predicted
SF-36 PCS 1.0 -- -- -- -- -- --
SF-36 MCS 0.22 1.0 -- -- -- -- --
SGRQ Total -0.62 -0.42 1.0 -- -- -- --
EQ-5D VAS 0.73 0.49 -0.63 1.0 -- -- --
EQ-5D index 0.64 0.58 -0.61 0.68 1.0 -- --
FEV1 % predicted 0.30 0.10 -0.34 0.38 0.26 1.0 --
FVC % predicted 0.32 0.08 -0.37 0.36 0.22 0.81 1.0
0
20
40
60
29-45 49-50 58-59 64-65 73-74 79-80
Age groups (years)
Better p = 0.0047 (all age groups)Health and Quality of Life Outcomes 2005, 3:56 http://www.hqlo.com/content/3/1/56
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stroke, Parkinson's disease and coronary heart disease, has
been examined [22]. It was concluded that in Parkinson's
disease the relationship between disease severity and
HRQL is linear, whereas in other diseases, such as chronic
coronary heart disease, a non-linear relationship was
observed. One of the most important implications of a
non-linear relationship is that similar changes in disease
severity may have a different effect on measured HRQL.
Comparing other studies with the present results, some
results highlight the fact that physical functioning is one
of the most important predictors of HRQL in older sub-
jects. The present results add the clinical value of multidi-
mensional and complex measures of HRQL as previously
described [23]. A moderate association between HRQL
and COPD severity stage using FEV1 % predicted was seen
in another study; however, a large variation in deteriora-
tion was observed within each stage of severity, indicating
that both clinical and HRQL measures should be consid-
ered in the assessment of these patients [24]. In a study by
Mahler et al, the decline in lung function over time may
predict various components of general HRQL [25].
On the other hand, only a few studies have highlighted a
relationship between disease severity and HRQL in
COPD. A recent publication supports our findings by
showing that GOLD stages of COPD severity differ signif-
icantly in SGRQ [26]. However, it was observed that the
upper limit of stage IV marks a threshold for dramatic
worsening of HRQL, whereas a change from stage 0 to II
does not correspond to any meaningful difference in
HRQL.
A moderate relationship between the disease stage of
COPD and HRQL was found [27]. Our findings confirm
these results as patients with COPD have significant
decreases in HRQL, and the latter deteriorates in parallel
with lung function impairment. An observational study
was conducted to explore the relationship between vari-
ous determinants of disease severity and HRQL [28].
According to its results, lung function and HRQL express
several different aspects of disease severity in COPD.
As was found in a study of asthma [29], no gender differ-
ence was seen in our study. However, this is not always the
case, as women tend to be more sensitive to changes in
HRQL [30].
Smoking status did not affect the subjects' HRQL in the
present study once COPD had been established. There are
various results for the association between smoking status
and HRQL. One study showed that COPD patients who
continue smoking have a significantly lower HRQL than
those who quit smoking [31]. On the other hand, current
smoking has been associated with a better HRQL in the
study by Wijnhoven et al. [28]. The explanation given was
that subjects who do not quit smoking might be those
with a less severe stage of disease. One limitation with the
present results might be the low number of subjects in the
very severe stage group, however, the ANCOVA analysis
compensate for the skew distribution.
The correlations between lung function and HRQL have
been shown to be weak in a number of studies [21]. In the
present study the SGRQ Total score ranged from 23 in
GOLD stage I to 56 in GOLD stage IV (according to BTS
23–47). The correlation between FEV1 % predicted and
the HRQL measurement varied between -0.34 and 0.10,
with the highest correlation (-0.34) between FEV1  %
predicted and SGRQ Total score. One reason for the differ-
ence in correlation between lung function and HRQL may
be the influence of psychosocial variables on the HRQL
outcome. The subjects in our study seemed to score their
HRQL better compared to other subject groups with sim-
ilar lung function. One study supported the view that the
association between lung function and HRQL can be pre-
dicted by perceived self-efficacy for functional activities
[32]. That study suggested that both biomedical and
psychosocial influences should be taken into account in
order to provide optimum assessment and treatment. The
correlations in this study were stronger than previous seen
and another reason might be that disease severity was con-
sidered as a category rather than a continuous variable.
Using FVC % predicted did not add any additional infor-
mation; however, it supported the view that the level of
lung function measured by volume has a similar but lower
association with HRQL compared with FEV1 in subjects
with COPD.
Conclusion
In conclusion, the results show that the level of health-
related quality of life of COPD subjects deteriorates con-
siderably with increasing severity of disease and that the
deterioration is linearly related to a decrease in FEV1 %
predicted normal values. A higher age also affected the
COPD subjects' HRQL, while gender, smoking status and
socio-economic group did not, once COPD had been
established.
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